Price cuts for these much-needed drugs will not only save money for the Chinese central government, which is dealing with the challenges
of addressing the medical needs
of an
aging population, but it will also increase access to innovative medicines for those who could not previously afford them.
Initially there were five companies involved in the negotiations, including the three companies included in this agreement, in addition to Celgene and Roche.